1. Home
  2. MLYS vs ZKH Comparison

MLYS vs ZKH Comparison

Compare MLYS & ZKH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MLYS
  • ZKH
  • Stock Information
  • Founded
  • MLYS 2019
  • ZKH 1998
  • Country
  • MLYS United States
  • ZKH China
  • Employees
  • MLYS N/A
  • ZKH N/A
  • Industry
  • MLYS Biotechnology: Pharmaceutical Preparations
  • ZKH
  • Sector
  • MLYS Health Care
  • ZKH
  • Exchange
  • MLYS Nasdaq
  • ZKH Nasdaq
  • Market Cap
  • MLYS 590.3M
  • ZKH 626.6M
  • IPO Year
  • MLYS 2023
  • ZKH 2023
  • Fundamental
  • Price
  • MLYS $11.87
  • ZKH $3.83
  • Analyst Decision
  • MLYS Strong Buy
  • ZKH Strong Buy
  • Analyst Count
  • MLYS 2
  • ZKH 2
  • Target Price
  • MLYS $30.00
  • ZKH $12.65
  • AVG Volume (30 Days)
  • MLYS 255.3K
  • ZKH 51.6K
  • Earning Date
  • MLYS 11-11-2024
  • ZKH 11-22-2024
  • Dividend Yield
  • MLYS N/A
  • ZKH N/A
  • EPS Growth
  • MLYS N/A
  • ZKH N/A
  • EPS
  • MLYS N/A
  • ZKH N/A
  • Revenue
  • MLYS N/A
  • ZKH $1,213,635,386.00
  • Revenue This Year
  • MLYS N/A
  • ZKH $4.02
  • Revenue Next Year
  • MLYS N/A
  • ZKH $16.24
  • P/E Ratio
  • MLYS N/A
  • ZKH N/A
  • Revenue Growth
  • MLYS N/A
  • ZKH 2.49
  • 52 Week Low
  • MLYS $6.06
  • ZKH $2.62
  • 52 Week High
  • MLYS $16.91
  • ZKH $21.91
  • Technical
  • Relative Strength Index (RSI)
  • MLYS 41.32
  • ZKH 53.21
  • Support Level
  • MLYS $11.30
  • ZKH $3.65
  • Resistance Level
  • MLYS $13.06
  • ZKH $3.94
  • Average True Range (ATR)
  • MLYS 1.01
  • ZKH 0.21
  • MACD
  • MLYS -0.22
  • ZKH -0.02
  • Stochastic Oscillator
  • MLYS 14.43
  • ZKH 42.35

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking three or more antihypertensive medications typically including a diuretic.

About ZKH ZKH Group Limited each representing thirty-five (35)

ZKH Group Ltd engages in providing MRO procurement service platform in China. It provides one-stop MRO procurement and management services for its customers, and offers digital and fulfillment solutions for participants along the industry value chain. It offers a broad range of MRO product offerings covering all MRO product lines on its platform, including spare parts, chemicals, manufacturing parts, general consumables, and office supplies. All of the Group's revenues are derived from the PRC.

Share on Social Networks: